BR9810729A - Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante - Google Patents

Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante

Info

Publication number
BR9810729A
BR9810729A BR9810729-1A BR9810729A BR9810729A BR 9810729 A BR9810729 A BR 9810729A BR 9810729 A BR9810729 A BR 9810729A BR 9810729 A BR9810729 A BR 9810729A
Authority
BR
Brazil
Prior art keywords
self
pharmaceutical composition
emulsifying formulation
composition
pharmaceutically acceptable
Prior art date
Application number
BR9810729-1A
Other languages
English (en)
Other versions
BR9810729B1 (pt
Inventor
Walter Morozowich
Ping Gao
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9810729A publication Critical patent/BR9810729A/pt
Publication of BR9810729B1 publication Critical patent/BR9810729B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

<B>COMPOSIçãO FARMACêUTICA PARA COMPOSTOS LIPOFìLICOS áCIDOS DISPOSTA COMO UMA FORMULAçãO AUTO-EMULSIFICANTE A presente invenção provê uma nova composição farmacêutica com base no uso de uma quantidade específica de amina básica que compreende um composto piranona como um agente farmaceuticamente ativo, uma amina básica em uma quantidade de cerca de 0,1% a cerca de 10% em peso da composição total, um ou mais solventes farmaceuticamente aceitáveis e um ou mais tensoativos farmaceuticamente aceitáveis. Além disto, a composição pode compreender, ainda, um ou mais óleos farmaceuticamente aceitáveis. A composição está disposta como uma formulação auto-emulsificante que provê alta concentração e biodisponibilidade oral para compostos piranona lipofílicos.
BRPI9810729-1A 1997-07-29 1998-07-27 composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante. BR9810729B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5401297P 1997-07-29 1997-07-29
PCT/US1998/014817 WO1999006044A1 (en) 1997-07-29 1998-07-27 Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation

Publications (2)

Publication Number Publication Date
BR9810729A true BR9810729A (pt) 2000-08-08
BR9810729B1 BR9810729B1 (pt) 2010-07-13

Family

ID=21988155

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9810729-1A BR9810729B1 (pt) 1997-07-29 1998-07-27 composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.

Country Status (25)

Country Link
US (1) US6231887B1 (pt)
EP (1) EP0989851B1 (pt)
JP (1) JP4524367B2 (pt)
KR (1) KR100509131B1 (pt)
CN (1) CN1112927C (pt)
AT (1) ATE225174T1 (pt)
AU (1) AU728626B2 (pt)
BR (1) BR9810729B1 (pt)
CA (1) CA2294033C (pt)
CY (1) CY2006002I2 (pt)
CZ (1) CZ296957B6 (pt)
DE (1) DE69808463T2 (pt)
DK (1) DK0989851T3 (pt)
ES (1) ES2184310T3 (pt)
FI (1) FI20000172A (pt)
HK (1) HK1028879A1 (pt)
HU (1) HU228923B1 (pt)
NO (1) NO323425B1 (pt)
NZ (1) NZ502566A (pt)
PL (1) PL192865B1 (pt)
PT (1) PT989851E (pt)
RU (1) RU2202346C2 (pt)
SI (1) SI0989851T1 (pt)
SK (1) SK284616B6 (pt)
WO (1) WO1999006044A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
DE60017720T2 (de) * 1999-03-31 2006-01-12 Pharmacia & Upjohn Co., Kalamazoo Pharmazeutische emulsionen für retroviral-protease hemmende verbindungen
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
AU2002230918B2 (en) * 2000-10-31 2006-12-14 Boehringer Ingelheim Pharmaceuticals, Inc. Oral self-emulsifying formulations of pyranone protease inhibitors
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
RS20050741A (en) * 2003-04-02 2007-06-04 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for hepatitis c viral protease inhibitors
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
WO2005036980A1 (en) * 2003-10-07 2005-04-28 Eli Lilly And Company Liquid formulations of ractopamine
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
EP1814549A2 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
CA2586501A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
JP5028885B2 (ja) * 2006-07-04 2012-09-19 大正製薬株式会社 ユビデカレノン含有自己乳化組成物
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
MA33491B1 (fr) * 2009-07-07 2012-08-01 Boehringer Ingelheim Int Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
RU2419426C1 (ru) * 2010-04-26 2011-05-27 Всеволод Иванович Киселев Лекарственное средство на основе дииндолилметана (dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
KR101752944B1 (ko) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
BR112015015864B1 (pt) * 2013-01-14 2022-08-23 Infirst Healthcare Limited Uso de uma composição farmacêutica no tratamento de uma condição de dor severa

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
DE3300793A1 (de) * 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
WO1996003113A1 (en) * 1994-07-22 1996-02-08 G.D. Searle & Co. Self-emulsifying drug delivery system
WO1996033697A1 (fr) * 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
EA001413B1 (ru) 1995-06-06 2001-02-26 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, содержащая ингибитор протеиназы и моноглицерид
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
EP0989851A1 (en) 2000-04-05
CZ2000156A3 (cs) 2000-05-17
PT989851E (pt) 2002-12-31
CY2006002I2 (el) 2012-01-25
DE69808463D1 (de) 2002-11-07
NZ502566A (en) 2002-03-28
US6231887B1 (en) 2001-05-15
PL338335A1 (en) 2000-10-23
HU228923B1 (en) 2013-06-28
NO20000466L (no) 2000-03-28
BR9810729B1 (pt) 2010-07-13
EP0989851B1 (en) 2002-10-02
CN1261796A (zh) 2000-08-02
DE69808463T2 (de) 2003-06-26
NO20000466D0 (no) 2000-01-28
CA2294033A1 (en) 1999-02-11
ATE225174T1 (de) 2002-10-15
NO323425B1 (no) 2007-04-30
CN1112927C (zh) 2003-07-02
HUP0002440A3 (en) 2001-10-29
RU2202346C2 (ru) 2003-04-20
AU728626B2 (en) 2001-01-11
CA2294033C (en) 2007-01-09
HK1028879A1 (en) 2001-03-09
SK284616B6 (sk) 2005-07-01
HUP0002440A2 (hu) 2001-09-28
JP2002510330A (ja) 2002-04-02
ES2184310T3 (es) 2003-04-01
DK0989851T3 (da) 2003-01-27
FI20000172A (fi) 2000-01-28
PL192865B1 (pl) 2006-12-29
KR20010022369A (ko) 2001-03-15
JP4524367B2 (ja) 2010-08-18
WO1999006044A1 (en) 1999-02-11
SK162000A3 (en) 2000-12-11
SI0989851T1 (en) 2003-04-30
CY2006002I1 (el) 2011-02-02
KR100509131B1 (ko) 2005-08-18
CZ296957B6 (cs) 2006-08-16
AU8573898A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
BR9810729A (pt) Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante
BR9811058A (pt) Formulação auto-emulsificante para compostos lipofìlicos
BR9810866A (pt) Composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
BR9813947A (pt) Composições tópicas para distribuição de droga nsai
AR062931A2 (es) Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
BRPI0116237B8 (pt) &#34;composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina&#34;.
BR0107445A (pt) Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco
DE50005515D1 (de) Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BR9911326A (pt) Análogos macrocìclicos e métodos para seu uso e preparação
ATA189395A (de) Orale pharmazeutische zubereitung
HRP20010243B1 (en) Compositions containing diphosphonic acids
BRPI0409440A (pt) composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença
BR9916830A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos e budesonide
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
BR0211729A (pt) Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
ATE364391T1 (de) Arzneiformulierung enthaltend ciclosporin und deren verwendung
BR9810711A (pt) Formulação tópica de pulverização antipruriginosa, e, processo para prevenção ou tratamento de prurido em um paciente
KR950031084A (ko) 국소용 진양(鎭洋) 조성물
DK0853476T3 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse
BR0016241A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
BR9803129A (pt) Composto de (17alfa) - 17 hidróxi-11 metileno-19 norpregna-4,15-dieno-20-in-3-ona cristalino, composição farmacêutica sólida e processo para a preparação e uso do composto de (17alfa)-17-hidróxi-11-metileno-19 norpregna-4, 15-dieno-20-in-3-ona cristalino.
KR970705394A (ko) 연고제 (an ointment preparation)
SE8302976L (sv) Farmaceutiska kompositioner innehallande minst en polyflourerad alkohol

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/07/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: PHARMACIA AND UPJOHN COMPANY LLC (US)

Free format text: NOME ALTERADO DE: PHARMACIA AND UPJOHN COMPANY

B25G Requested change of headquarter approved

Owner name: PHARMACIA AND UPJOHN COMPANY LLC (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020120005559/RJ DE 23/01/2012.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13.07.2020